| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Revenue | $7.08B | -14.2% |
| Cost of Revenue | $3.87B | -11.5% |
| Gross Profit | $3.22B | -17.2% |
| R&D Expense | $612.7M | +6.1% |
| SG&A Expense | $376.3M | +3.8% |
| Operating Income | $1.77B | -30.4% |
| Pre-tax Income | $1.84B | -27.5% |
| Income Tax | $262.8M | -25.0% |
| Net Income | $1.57B |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $2.69B | +8.4% |
| Short-term Investments | $300.0M | — |
| Accounts Receivable | $1.16B | +24.0% |
| Inventory | $2.24B | +6.2% |
| Current Assets | $6.75B | +14.2% |
| Total Assets | $14.09B | +6.6% |
| Current Liabilities | $1.33B | -38.9% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | $1.91B | -3.6% |
| Capital Expenditures | $694.0M | -56.0% |
| Investing Cash Flow | -$1.01B | +41.9% |
| Financing Cash Flow | -$683.8M | +0.4% |
| Free Cash Flow | $1.21B | +201.7% |
| -28.0% |
| EPS (Basic) | $3.68 | -27.4% |
| EPS (Diluted) | $3.63 | -25.8% |
| Long-term Debt |
| $3.38B |
| +0.0% |
| Total Liabilities | $5.28B | -2.6% |
| Stockholders' Equity | $8.80B | +13.0% |